Preliminary Evaluation of

Prostate-specific membrane antigen (PSMA) is a promising molecular target for imaging of prostate adenocarcinoma.Patients were enrolled into two cohorts. The biodistribution cohort included 8 treated prostate cancer patients without recurrence, who underwent 6 whole body PET/CT scans with urine sampling for dosimetry using OLINDA/EXM. The dynamic cohort included 15 patients with BCR and 2 patients with primary prostate cancer. Two patients with renal cell carcinoma were also enrolled for exploratory use. A dynamic PET/CT was followed by 2 whole body scans for imaging protocol optimization based on bootstrapped replicates.Based on its favorable imaging characteristics and diagnostic performance in prostate cancer